Johnson & Johnson Dirección

Dirección controles de criterios 2/4

El CEO de Johnson & Johnson es Joaquin Duato , nombrado en Jan 2022, tiene una permanencia de 2.92 años. compensación anual total es $28.40M, compuesta por 5.6% salario y 94.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.015% de las acciones de la empresa, por valor de $56.47M. La antigüedad media del equipo directivo y de la junta directiva es de 5 años y 5 años, respectivamente.

Información clave

Joaquin Duato

Chief Executive Officer (CEO)

US$28.4m

Compensación total

Porcentaje del salario del CEO	5.6%
Permanencia del CEO	2.9yrs
Participación del CEO	0.02%
Permanencia media de la dirección	5yrs
Promedio de permanencia en la Junta Directiva	5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Joaquin Duato en comparación con los beneficios de Johnson & Johnson?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 29 2024	n/a	n/a	US$15b
Jun 30 2024	n/a	n/a	US$16b
Mar 31 2024	n/a	n/a	US$17b
Dec 31 2023	US$28m	US$2m	US$13b
Oct 01 2023	n/a	n/a	US$12b
Jul 02 2023	n/a	n/a	US$12b
Apr 02 2023	n/a	n/a	US$11b
Jan 01 2023	US$13m	US$1m	US$16b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$18b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Compensación vs. Mercado: La compensación total de Joaquin($USD28.40M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD5.75M).

Compensación vs. Ingresos: La compensación de Joaquin ha aumentado más de un 20% en el último año.

CEO

Joaquin Duato (61 yo)

2.9yrs

Permanencia

US$28,397,240

Compensación

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Joaquin Duato	CEO & Chairman	2.9yrs	US$28.40m	0.015% $ 56.5m
Joseph Wolk	Executive VP & CFO	6.4yrs	US$13.91m	0.0029% $ 11.0m
Peter Fasolo	Executive VP & Chief Human Resources Officer	8.7yrs	US$7.50m	0.0047% $ 17.4m
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12.9yrs	US$11.00m	0.0064% $ 24.0m
John Reed	Executive Vice President of Innovative Medicine	1.7yrs	US$20.65m	0.00061% $ 2.3m
Robert Decker	Controller & Chief Accounting Officer	5yrs	sin datos	0.00082% $ 3.1m
James Swanson	Executive VP & Chief Information Officer	5.1yrs	sin datos	0.00061% $ 2.3m
Jessica Moore	Vice President of Investor Relations	3.1yrs	sin datos	sin datos
Dirk Brinckman	Chief Compliance Officer	no data	sin datos	sin datos
Elizabeth Forminard	Executive VP & Chief Legal Officer	2.2yrs	sin datos	0.00035% $ 1.3m
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	sin datos	sin datos
Kathryn Wengel	Executive VP and Chief Technical Operations & Risk Officer	6.4yrs	sin datos	0.0034% $ 12.8m

5.0yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0R34 es experimentado (5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Joaquin Duato	CEO & Chairman	2.9yrs	US$28.40m	0.015% $ 56.5m
Anne Mulcahy	Independent Director	15.9yrs	US$410.00k	0.00034% $ 1.3m
Hubert Joly	Independent Director	5yrs	US$320.00k	0.00021% $ 783.7k
Marillyn Hewson	Lead Independent Director	5.7yrs	US$360.00k	0.00012% $ 447.8k
Paula Johnson	Independent Director	1.8yrs	US$352.97k	0.000010% $ 37.3k
Mark McClellan	Independent Director	11.2yrs	US$320.00k	0% $ 0
Mary Beckerle	Independent Director	9.5yrs	US$355.00k	0% $ 0
Darius Adamczyk	Independent Director	2.8yrs	US$340.00k	0.000040% $ 149.3k
Jennifer Doudna	Independent Director	6.7yrs	US$320.00k	0% $ 0
Eugene Woods	Independent Director	1.1yrs	US$89.15k	sin datos
Mark Weinberger	Independent Director	5yrs	US$340.00k	0% $ 0
Nadja West	Independent Director	4yrs	US$340.00k	0% $ 0

5.0yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 0R34 se considera experimentada (5 años de antigüedad promedio).

Johnson & Johnson Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson Announces Executive Changes

Recent updates

Johnson & Johnson Seeks U.S. FDA Approval for First Pediatric Indications for TREMFYA (Guselkumab)

Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya (Guselkumab) inulcerative Colitis, A First for an IL-23 Inhibitor

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Results from Additional Analyses of the Phase 2 DAHLIA Study Highlighting Improvement in Key Measures of Disease Activity and IgG Reduction

Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya

Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress

Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis

Third quarter dividend of US$1.24 announced

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Third quarter 2024 earnings released: EPS: US$1.11 (vs US$1.71 in 3Q 2023)

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad